Webinar: Reimagining Gene-Modified T Cell Manufacturing – New Data on Integrating Isolation, Activation, Transduction, and Expansion in a Single Quantum Flex™ Workflow

Discover new data showcasing a streamlined approach to gene-modified T cell manufacturing that brings together multiple critical unit operations into a single, integrated workflow.

In this webinar, we will present the first demonstration of incorporating T cell isolation upstream of Quantum Flex™ processing, extending automation and process integration from cell selection through expansion.

Starting with Leukopak material collected on the Spectra Optia®, CD3+ T cells were isolated using a negative selection buoyancy-based microbubble separation method. For this autologous process, under 10 million isolated and activated T cells were then directly introduced into the Quantum Flex system, where they underwent lentiviral transduction and subsequent expansion to a therapeutically relevant dose.

Attendees will gain insight into how this integrated, closed-system approach compares with traditional static culture methods and explore data highlighting key process advantages. The workflow is designed to reduce operator intervention, minimize hands-on processing time, and shorten the path from starting material to target cell dose. In 

addition, the process demonstrates robust expansion from a relatively small starting cell number while maintaining critical quality attributes throughout manufacturing.

By combining cell isolation, activation, transduction, and expansion into a streamlined workflow, this approach has the potential to simplify manufacturing operations, reduce open handling steps, and support greater process consistency. The presentation will also discuss how integrating buoyant microbubble-based T cell isolation with the Quantum Flex platform may help advance scalable manufacturing strategies for gene-modified T cell therapies.

Join us to explore how an end-to-end, closed-system workflow could help transform the manufacturing landscape for next-generation cell therapies through greater efficiency, flexibility, and process integration.